Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis
Open Access
- 1 July 2017
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 153 (1) , 49-52.e5
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24Annals of the Rheumatic Diseases, 2014
- Therapy for Hepatitis C Virus–Related Cryoglobulinemic VasculitisNew England Journal of Medicine, 2013
- A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitisArthritis & Rheumatism, 2011
- Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced VasculitisNew England Journal of Medicine, 2011
- Relapse of hepatitis C virus–associated mixed cryoglobulinemia vasculitis in patients with sustained viral responseArthritis & Rheumatism, 2008
- Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitisCurrent Opinion in Rheumatology, 2008
- Unique NS5b Hepatitis C Virus Gene Sequence Consensus Database Is Essential for Standardization of Genotype Determinations in Multicenter Epidemiological StudiesJournal of Clinical Microbiology, 2006
- Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathyClinical Therapeutics, 2005
- Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis CHepatology, 1994
- Biologic and clinical significance of cryoglobulinsThe American Journal of Medicine, 1974